

Martina Fabris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7058809/publications.pdf>

Version: 2024-02-01

61
papers

2,282
citations

172207

29
h-index

223531

46
g-index

62
all docs

62
docs citations

62
times ranked

3128
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 526-531.	0.5	248
2	Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1507-1513.	2.8	197
3	BlyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. <i>Rheumatology</i> , 2013, 52, 276-281.	0.9	125
4	Characterization of the Proinflammatory Profile of Synovial Fluid-Derived Exosomes of Patients with Osteoarthritis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	1.4	90
5	Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1557-1559.	0.9	87
6	Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. <i>Israel Medical Association Journal</i> , 2020, 22, 203-210.	0.1	77
7	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015, 54, kev257.	0.9	66
8	Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjogren's Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma. <i>Open Rheumatology Journal</i> , 2008, 2, 38-43.	0.1	60
9	Hepatitis C virus infection, mixed cryoglobulinemia and BlyS upregulation: Targeting the infectious trigger, the autoimmune response, or both?. <i>Autoimmunity Reviews</i> , 2008, 8, 95-99.	2.5	59
10	The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2018, 17, 541-547.	2.5	55
11	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1847-50.	1.0	53
12	The 158VV Fc gamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 716-721.	0.5	52
13	Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. <i>Journal of Autoimmunity</i> , 2006, 26, 182-196.	3.0	51
14	Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 490-4.	0.4	51
15	Role of oral cyclophosphamide in the treatment of giant cell arteritis. <i>Rheumatology</i> , 2012, 51, 1677-1686.	0.9	49
16	Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. <i>Rheumatology</i> , 2015, 54, 1429-1434.	0.9	49
17	Role of Fms-like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatism</i> , 2013, 65, 3218-3227.	6.7	46
18	Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. <i>Cytokine</i> , 2021, 140, 155438.	1.4	44

#	ARTICLE	IF	CITATIONS
19	The CC homozygosis of the $\hat{\sim}174G\hat{>}C$ IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 315-320.	2.5	43
20	Specific chemoluminescence and immunoasorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. <i>Clinica Chimica Acta</i> , 2015, 451, 271-277.	0.5	43
21	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 29-33.	1.0	43
22	Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. <i>Neurodegenerative Diseases</i> , 2017, 17, 227-234.	0.8	42
23	The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0113821.	1.8	36
24	Preliminary Classification of Nonmalignant B Cell Proliferation in Sjögren's Syndrome: Perspectives on Pathobiology and Treatment Based on an Integrated Clinico-Pathologic and Molecular Study Approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 757-766.	0.6	35
25	Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation. <i>International Journal of Rheumatology</i> , 2009, 2009, 1-8.	0.9	35
26	Post-“COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1140-1148.	2.8	35
27	$\hat{\sim}238$ and +489 TNF- $\hat{\pm}$ along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. <i>Immunology Letters</i> , 2005, 96, 103-108.	1.1	33
28	Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. <i>Rheumatology</i> , 2012, 51, 627-633.	0.9	33
29	Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. <i>Journal of Immunological Methods</i> , 2016, 436, 50-53.	0.6	33
30	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. <i>Digestive and Liver Disease</i> , 2007, 39, S122-S128.	0.4	32
31	Anti-zinc transporter protein 8 autoantibodies significantly improve the diagnostic approach to type 1 diabetes: an Italian multicentre study on paediatric patients. <i>Autoimmunity Highlights</i> , 2015, 6, 17-22.	3.9	30
32	Transforming growth factor \hat{I}^2 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R111.	1.6	29
33	Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. <i>Autoimmunity Highlights</i> , 2010, 1, 87-94.	3.9	27
34	Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1434-1439.	0.6	25
35	The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation. <i>Autoimmunity Highlights</i> , 2014, 5, 63-67.	3.9	25
36	The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics. <i>Autoimmunity Highlights</i> , 2016, 7, 9.	3.9	24

#	ARTICLE	IF	CITATIONS
37	Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes. <i>Scientific Reports</i> , 2019, 9, 8457.	1.6	23
38	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013, 65, 88-97.	6.7	22
39	Long-Term Effects of Rituximab in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 692-700.	1.8	21
40	Anti-DFS70 Antibodies: A Useful Biomarker in a Pediatric Case With Suspected Autoimmune Disease. <i>Pediatrics</i> , 2014, 134, e1706-e1708.	1.0	20
41	Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2597-2604.	1.3	19
42	Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. <i>Haematologica</i> , 2006, 91, 691-4.	1.7	15
43	New genetically engineered DFS70 knock-out HEp-2 cells enable rapid and specific recognition of anti-DFS70 antibodies. <i>Autoimmunity</i> , 2018, 51, 152-156.	1.2	14
44	A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: A pilot study. <i>Autoimmunity Reviews</i> , 2020, 19, 102588.	2.5	10
45	Seroconversion and kinetic of anti SARS-CoV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-CoV-2 infection. <i>Hematological Oncology</i> , 2021, 39, 428-431.	0.8	8
46	Circulating exosomes express $\alpha 4 \beta 7$ integrin and compete with CD4+ T cells for the binding to Vedolizumab. <i>PLoS ONE</i> , 2020, 15, e0242342.	1.1	8
47	B-Lymphocyte Stimulator and a Proliferation-Inducing Ligand Serum Levels in IgA-Deficient Patients With and Without Celiac Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 268-273.	1.8	7
48	CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial. <i>International Immunopharmacology</i> , 2021, 98, 107874.	1.7	7
49	Pericardial Cytokine "Storm" in a COVID-19 Patient: the Confirmation of a Hypothesis. <i>Inflammation</i> , 2022, 45, 1-5.	1.7	7
50	Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies. <i>Autoimmunity Highlights</i> , 2017, 8, 5.	3.9	6
51	Anti- $\beta 2$ -glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells. <i>Autoimmunity Highlights</i> , 2019, 10, 3.	3.9	6
52	Positive tissue transglutaminase antibodies with negative endomysial antibodies: Unresolved issues in diagnosing celiac disease. <i>Journal of Immunological Methods</i> , 2021, 489, 112910.	0.6	5
53	Diagnosing and Monitoring Celiac Patients with Selective IgA Deficiency: Still an Open Issue. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3234-3241.	1.1	5
54	Il test ANA-reflex. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2015, 11, 171-175.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2018, 18, 618-625.	0.6	3
56	Current technologies for anti-ENA antibody detection: State-of-the-art of diagnostic immunoassays. <i>Journal of Immunological Methods</i> , 2022, 507, 113297.	0.6	3
57	Up-Regulation of B-Lymphocyte Stimulator (BLyS) in Patients with Mixed Cryoglobulinemia. , 2012, , 119-126.		0
58	Title is missing!. , 2020, 15, e0242342.		0
59	Title is missing!. , 2020, 15, e0242342.		0
60	Title is missing!. , 2020, 15, e0242342.		0
61	Title is missing!. , 2020, 15, e0242342.		0